glp 1 up ora GLP-1 Do GLP-1 Supplements Lead to

October 2025: semaglutide (Rybelsus) Novo Nordisk submitted a supplemental new drug application (sNDA) to the FDA for oral semaglutide (Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular [CV] death, non-fatal heart attack or non-fatal stroke) in people with type 2 diabetes (T2DM) and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD)

Eating Habits That Increase Air Swallowing Ozempic bloating could also be caused by more than what you eat

Concentrated sweat and urine can smell stronger

Nevertheless, more studies emerge on the role of GLP-1 in mucosal integrity and modulation of inflammatory response and suggest that it may become an equally important tool in the IBD therapy